ACIU · AC Immune SA · Metrics
Market Cap
$246.58M
Shares
99.43M
Volume · Oct 20
140.11K
Avg daily vol (3M)
195.59K
ACIU metrics
65 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$2.49
Market cap
$246.58M
Price action
20 metricsPrice change (1W)
-0.6%
Price change (30D)
-8.3%
Price change (3M)
+8.2%
Price change (6M)
-18.3%
Price change (YTD)
-22.5%
Price change (1Y)
-16.0%
Trailing year
Price change (5Y)
-59.7%
52-week high
$3.84
52-week low
$2.12
Change from 52-week high
-36.6%
Change from 52-week low
+14.9%
Annualized volatility
68.6%
Annualized volatility (3M)
55.2%
Beta
1.6
RSI (14D)
42.3
Price vs SMA 50
-7.8%
Price vs SMA 200
-12.3%
Avg volume (3M)
196,621
Relative volume
0.5
Average dollar volume
$508,791
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
99.43M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
10.9×
reciprocal yield 9.2%
P / book
5.5
reciprocal yield 18.2%
FCF yield
-26.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-22.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-252.2%
Trailing 12 months
Net margin
-246.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$44.15M
Net income (TTM)
−$54.40M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-291.8%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+90.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$22.07M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.3%
Year over year · more shares
Revenue CAGR (3Y)
-3.2%
Revenue CAGR (5Y)
-25.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-122.7%
Return on assets
-28.7%
Debt / equity
—
Current ratio
0.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$64.40M
Quick ratio
0.9
Interest coverage
-206.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$33.76M
Total assets
$186.09M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$63.65M
Capital expenditures (TTM)
$748,748
R&D (TTM)
$57.88M
SG&A (TTM)
—
Stock compensation (TTM)
$5.48M
R&D / revenue
262.2%
Stock compensation / revenue
24.8%
Ownership (13F)
9 metrics13F filers
43
13F filer change QoQ
-5
Institutional ownership
24.8%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-1.9%
Holder tenure
24.2
Price vs estimated holder cost
-13.7%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
3.5%
Latest settlement · 18.7 days to cover
Days to cover
18.7d
Short-squeeze score
63 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—